Recent Updates
Recently added Catalysts
PODD Positive Sentiment

Insulet Reports Third Quarter 2026 Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Insulet Corporation reported a revenue of $842.0 million for Q3 2026, reflecting a 19.2% increase compared to the previous year. This figure slightly surpassed the company's guidance range of 17.5% to 19.5% growth at constant currency rates. The Omnipod product line continues to drive significant revenue growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased by 19.2% year-over-year.
  • Results exceeded the company's guidance range.
  • Strong performance in the Omnipod product line.

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates Total Omnipod revenue o

Frequently Asked Questions

What was Insulet's revenue for Q3 2026?

Insulet reported a revenue of $842.0 million for Q3 2026.

How much did revenue increase year-over-year?

Revenue increased by 19.2% compared to the previous year.

Did Insulet meet its revenue guidance?

Yes, Insulet's revenue slightly exceeded its guidance range.

What product line contributed to Insulet's growth?

The Omnipod product line significantly contributed to revenue growth.

ShareAdd on Google
Tags: PODD Insulet Omnipod financial results revenue growth
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$535M liquidity · $0M/mo burn
Low dilution risk